T cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients.
Achiron
A
A
Multiple Sclerosis Center, Sheba Medical Center, Tel-Hashomer, Israel. achiron@post.tau.ac.il
Lavie
G
G
Kishner
I
I
Stern
Y
Y
Sarova-Pinhas
I
I
Ben-Aharon
T
T
Barak
Y
Y
Raz
H
H
Lavie
M
M
Barliya
T
T
Faibel
M
M
Cohen
I R
IR
Mandel
M
M
D000328:Adult; D001921:Brain / Q000473:pathology; D005260:Female; D006801:Humans; D016233:Immunotherapy, Active; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D004676:Myelin Basic Protein / Q000276:immunology; D009185:Myelin Proteins; D018992:Myelin-Associated Glycoprotein / Q000276:immunology; D063308:Myelin-Oligodendrocyte Glycoprotein; D013601:T-Lymphocytes / Q000276:immunology / Q000637:transplantation*; D016896:Treatment Outcome
C571326:MOG protein, human; D004676:Myelin Basic Protein; D009185:Myelin Proteins; D018992:Myelin-Associated Glycoprotein; D063308:Myelin-Oligodendrocyte Glycoprotein